Pharmaceutical processing of alpha-(2,4-dichlorophenyl)-1H-imidazole-1-ethanol as a chiral alcohol base requires distinct control strategies for oral solid dosage manufacture and injectable preparation. The compound has a molecular weight of 257.11 g/mol and an imidazole ring whose ionisation state is pH-dependent, which affects dissolution, partitioning, and salt selection during formulation. Publicly available finished-product monographs for this specific chemical entity are limited; the processing windows described below therefore combine applicable pharmacopoeial test designations with standard manufacturing behaviour for similar azole alcohol active ingredients. Materials should be released only after specification development under ICH Q6A and elemental impurity risk assessment under ICH Q3D.

Direct compression of an immediate-release tablet containing the API at 4.0–12.5% w/w is the shortest route for oral solid dosage manufacture, but it is also the most sensitive to segregation and particle size variation. The API is pre-milled or micronised to a particle size D90 ≤ 20 µm, then screened through a 30 mesh (600 µm) stainless-steel sieve before charging. A working direct-compression matrix consists of microcrystalline cellulose 40.0–60.0% w/w, lactose monohydrate 20.0–30.0% w/w, crospovidone 2.0–5.0% w/w, and magnesium stearate 0.5–1.0% w/w. Blending is performed in a bin blender at 10–20 rpm for 15–25 min; lubrication is added separately for the final 3–5 min and is limited to avoid over-lubrication. Tablet compression uses a rotary press with precompression force 5–10 kN and main compression force 10–25 kN, targeting hardness 80–120 N and friability below 1.0% per USP <1216>. In-process controls follow 21 CFR 211.110, with weight variation checked every 15–20 min; finished tablets are tested for content uniformity per USP <905> and dissolution per USP <711> using 0.1 N HCl as an initial medium where pH-dependent release is evaluated. If the unit dose is below 5 mg, a geometric dilution step with part of the lactose source is inserted before main blending; content uniformity failures on production batches are most commonly caused by omitting this pre-mix. Pre-drying at RH greater than 60% may be required because free moisture above 1.0% can increase sticking to punch faces. The terminal finished-product types are uncoated or aqueous film-coated immediate-release tablets; film coating with polyvinyl alcohol-based systems at 2.0–3.0% w/w weight gain is typical when the core shows friability below 0.8%.

What Limits Capsule Filling Accuracy in Direct Encapsulation of Low-Density API Powders?

Direct encapsulation of the API into hard gelatin or hydroxypropylmethylcellulose capsules is usually selected when the formulation cannot tolerate tablet compression forces or when a blend is intended for subsequent reconstitution. The powder bed is formulated at API 8.0–18.0% w/w, lactose monohydrate or mannitol q.s. to 100% w/w, colloidal silicon dioxide 0.5–1.5% w/w, and sodium starch glycolate 2.0–4.0% w/w. The limiting variable is not chemical stability of the imidazole alcohol but the low bulk density and electrostatic charge of the micronised fraction. On a production-scale dosator or tamping-pin capsule filler, fill weight variance increases sharply when the blend bulk density drops below 0.45 g/mL or when the angle of repose exceeds 35°. The blend is therefore passed through a cone mill equipped with a 0.8–1.0 mm mesh and equilibrated at 40–50% RH for 4–6 h before filling. Target fill weight is 250–400 mg, with specification limits of ±3.0% on individual capsule weight. In-process checks follow 21 CFR 211.110; finished capsules are tested for content uniformity per USP <905> and dissolution per USP <711>. Terminal product types are size 3 to 0 hard gelatin or hydroxypropylmethylcellulose capsules, optionally banded or sealed if the API is formulated with a moisture-sensitive granule component. Pre-drying is required at RH greater than 60% because free moisture in the blend can cause capsule shell embrittlement or crosslinking after storage. The direct-encapsulation process is not suitable for modified-release capsule formulations without prior granulation; the low cohesiveness of dry API blends makes brittle capsule shells prone to breakage at fill speeds above 80,000 capsules/h.

Wet Granulation and Extrusion-Spheronization for Modified-Release Granule Cores

Wet granulation of the alcohol base is performed when the oral dosage form must achieve higher bulk density, controlled dissolution, or uniform suspension of a multi-particulate intermediate. The granulation batch is formulated with API 6.0–15.0% w/w, microcrystalline cellulose 30.0–50.0% w/w, lactose monohydrate 15.0–30.0% w/w, hydroxypropylmethylcellulose 3.0–6.0% w/w, and croscarmellose sodium 2.0–5.0% w/w. Purified water or a 70:30 water-ethanol mixture is added to a high-shear granulator at 20–30% w/w of dry charge; impeller speed is maintained at 200–300 rpm and chopper speed at 1500–1800 rpm until torque reaches 4–6 N·m. The wet mass is extruded through a dome or radial screen with 0.8–1.2 mm apertures and then spheronized at 600–900 rpm for 3–6 min. Drying is carried out in a fluidized-bed dryer with inlet air at 60–70 °C until loss on drying is below 2.0% per USP <731>. Granule size distribution is controlled by Ph. Eur. 2.9.38 or USP <786>; compendial dissolution testing for the final granule-filled capsule or sachet uses USP <711>. Elemental impurities are controlled per ICH Q3D, and residual solvents are controlled per ICH Q3C. Terminal finished-product types are granule-filled capsules, sachet suspensions, and enteric-coated multi-particulate capsules. During pilot scale-up, the most frequent failure mode is over-granulation, which lowers dissolution release by forming dense cores larger than 1.4 mm; end-point torque should therefore be recorded on every batch and correlated with granule porosity. The granule process window is narrow at the drying stage: inlet air above 75 °C can cause surface hardening of granules while the core moisture remains above 2.0%, producing non-uniform dissolution across sub-lots.

Injectable solution manufacture of the API as a weakly basic alcohol requires pH adjustment and oxygen displacement because the imidazole ring can participate in oxidative degradation under headspace oxygen. A typical formulation contains API at 1.0–5.0 mg/mL, sodium chloride 0.9% w/v, optionally citrate buffer 10–20 mM at pH 4.0–5.5, and Water for Injection q.s. to volume. The vehicle is sparged with nitrogen and cooled to 20–25 °C; the API is added under agitation at 200–400 rpm until dissolved. pH adjustment with 0.1 N hydrochloric acid or sodium hydroxide is performed before volume make-up because the solubility of the neutral base decreases above pH 6.0. The solution is filtered through a 0.22 µm polyvinylidene fluoride or polyethersulfone cartridge, then filled into Type I glass ampoules or vials under ISO 14644-1:2015 Grade A environment. Terminal sterilisation by saturated steam at 121 °C for 15 min is applied only after stability data confirm that total degradation products remain below 0.5%; if pH-dependent hydrolysis is observed, aseptic filtration and filling are used instead. Where terminal sterilisation is used, the minimum lethality is F0 ≥ 8 min at 121 °C. Quality release includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, and USP <790> visible particulates. Terminal finished-product types are sterile solution ampoules for intravenous, intramuscular, or subcutaneous administration. Operational boundary: the filled solution should be protected from light if the API indicates photodegradation; avoid contact with stainless steel surfaces at pH below 2.5 for extended hold times because dissolved iron can initiate oxidative pathways. Filter integrity is confirmed by bubble point and diffusion testing before and after filling, and container closure integrity is evaluated under USP <1207>.

When Lyophilized Sterile Powder Is Selected Over Ready-to-Use Injection

Lyophilised sterile powder is selected when the aqueous solution of the alcohol base does not maintain the required impurity profile for the full shelf life at 2–8 °C or when the final product must be distributed in markets with limited cold-chain continuity. The pre-lyophilisation liquid contains API at 15–30% w/w of total solids, with mannitol 40–60% w/w and sucrose or trehalose 25–50% w/w as bulking and cryoprotectant agents; the pH is adjusted to 5.0–6.0 before 0.22 µm filtration. The solution is filled at 2–5 mL per 10 mL vial and loaded into a freeze dryer with shelf temperature ramped to -45 °C at 0.5–1.0 °C/min. Primary drying is performed at shelf temperature -20 °C and chamber pressure 150–250 µbar for 20–40 h; secondary drying at 25–35 °C for 6–12 h reduces residual moisture below 1.0% per USP <921>. The resulting cake should have a porosity sufficient to allow reconstitution in 20–60 s; collapse or melt-back on the production scale is most often linked to a eutectic point excursion during primary drying. Manufacturing operations are performed under EU GMP Annex 1 with lyophiliser loading and unloading in ISO 14644-1:2015 Grade A. Quality release includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, and USP <822> hypodermic needle gauge suitability after reconstitution. Terminal finished-product type is lyophilised powder for injection, reconstituted with 0.9% sodium chloride before administration. The most critical scale-up parameter is the difference between the product collapse temperature and the primary drying shelf temperature; if this difference is less than 3 °C, a design space should be verified by a lyophilisation process qualification rather than transferred from pilot-scale data.

High-Shear Homogenisation and Terminal Sterilisation for Lipid-Based Injectable Dispersions

Lipid-based injectable dispersions are investigated when the aqueous solubility of the un-ionized alcohol is insufficient for ready-to-use solutions and pH manipulation is not acceptable for the intended route. A typical formulation is composed of API 2.0–10.0 mg/g, medium-chain triglycerides 10.0–20.0% w/w, egg or purified soybean phospholipids 1.2–2.4% w/w, glycerol 2.25% w/w, and Water for Injection q.s. to 100%. A primary coarse emulsion is formed with a rotor-stator homogeniser at 10,000–15,000 rpm for 20–30 min under nitrogen; the coarse emulsion is then passed through a high-pressure homogeniser at 800–1200 bar for 10–15 cycles until the mean droplet size is below 200 nm as measured by photon correlation spectroscopy. The pH is adjusted to 5.0–7.0, and the dispersion is filled into Type I glass vials and terminally sterilised by rotary autoclave at 121 °C for 15 min; sterile filtration is generally not feasible for lipid droplets larger than 0.22 µm. Release testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, USP <729> globule size distribution, and USP <785> osmolality. Terminal finished-product type is intravenous lipid emulsion or nanosuspension for parenteral administration. The main scale-up failure is droplet growth during autoclaving; pre-autoclave mean droplet size must therefore remain below 150 nm to avoid exceeding the large-diameter tail limits defined in USP <729>. The process is not suitable when the API is sensitive to phospholipid peroxides or when terminal sterilisation causes unacceptable free fatty acid release above 2.0 mEq/L.